期刊文献+

非糖尿病合并冠心病患者血浆骨桥蛋白与冠状动脉严重程度的相关性 被引量:3

Associaton Between Plasma Osteopontin Levels and Severity of Coronary Heart Disease in Non-Diabetic Subjects
下载PDF
导出
摘要 目的探讨非糖尿病合并冠心病患者血浆骨桥蛋白水平与冠状动脉严重程度的相关性。方法入选166例因稳定型心绞痛入院的非糖尿病患者,采集一般临床资料和常规化验指标结果,通过酶联免疫吸附试验检测外周血骨桥蛋白水平。行冠状动脉造影明确冠心病,按照冠状动脉病变血管数进行严重程度分组:无冠状动脉病变组、单支冠状动脉病变组、双支冠状动脉病变组、三支冠状动脉病变组。冠状动脉钙化积分通过64排螺旋CT扫描机测定。按冠状动脉钙化积分分组:无钙化组(〈10)、轻度钙化组(11~100)、中度钙化组(101~400)和重度钙化组(〉400)。结果随着冠状动脉狭窄程度和钙化程度的加重,血浆骨桥蛋白水平呈升高趋势。血浆骨桥蛋白水平与非糖尿病合并冠心病患者冠状动脉狭窄严重程度(r=0.50,P〈0.01)及冠状动脉钙化积分呈正相关(r=0.38,P〈0.01)。结论血浆骨桥蛋白水平可能是非糖尿病合并冠心病患者冠状动脉狭窄及钙化程度的独立危险因素。 Aim To seek the association between plasma osteopontin( OPN) levels and severity of coronary heart disease in non-diabetic subjects. Methods A total of 166 stable angina patients free of diabetes were enrolled in the study. Clinical characteristic of patients was recorded. Plasma OPN levels were measured by an enzyme-linked immunosorbent assay method. Coronary heart disease was determined by coronary artery angiography. The extent of coronary artery stenosis was represented as the numbers of 50% stenotic vessels. Coronary artery clacification was evaluated by 64slice spiral CT. The coronary artery clacification scores were classified into 4 categories on the basis of their severity: no calcification( ≤10),mild calcification( 11 ~ 100),moderate( 101 ~ 400),severe( 400). Results As the severity of coronary artery calcification and coronary stenosis,plasma OPN levels were increased. Plasma OPN levels were positively associated with coronary artery calcification and coronary stenosis. Conclusion Plasma OPN levels can be considered as an independent factor of coronary artery calcification and coronary stenosis in coronary heart disease patient without diabetes.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2014年第5期477-479,共3页 Chinese Journal of Arteriosclerosis
基金 国家自然科学基金(81170254 81300227)资助项目 江苏省社会发展基金(BE2011793)资助项目
关键词 骨桥蛋白 冠心病 稳定型心绞痛 血管钙化 Osteopontin Coronary Heart Disease Stable Angina Calcification
  • 相关文献

参考文献10

  • 1文伟明,雷敏,徐戈,李志乐.烟酸对实验性动脉粥样硬化兔主动脉骨桥蛋白表达的影响[J].中国动脉硬化杂志,2013,21(2):149-153. 被引量:3
  • 2Ikeda T, Shirasawa T, Esaki Y, et al. Osteopontin mRNA is ex- pressed by smooth muscle-derived foam cells in human atherosclerotie lesions of the aorta [J]. J Clin Invest, 1993, 92(6) : 2 814-820.
  • 3Wada T, McKee MD, Steitz S, et al. Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin [ J ]. Cite Res, 1999, 84(2) : 166-178.
  • 4Berezin AE, Kremzer AA. Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus pa- tients with known asymptomatic coronary artery disease [ J ]. Athero- sclerosis, 2013, 229(2) : 475-481.
  • 5Qiu ZB, Xu H, Duan C, et al. Osteopontin is required for angioten- sin II-induced migration of vascular smooth muscle cells [ J ]. Pharmazie, 2012, 67(6) : 553-558.
  • 6孙玲,郭大璘,李保,郝菲,韩威,吴江,窦勇,季冰,王瑞团.血浆骨桥蛋白水平与冠状动脉钙化及其严重程度的关系[J].中国药物与临床,2012,12(6):814-816. 被引量:8
  • 7Haberl R, Becker A, Leber A, et al. Correlation of coronary calcifi- cation and angiographically documented stenosis in patients with sus- pected coronary artery disease: results of 1764 patients [ J]. J Am Coil Cardiol, 2001, 37(2) : 451-457.
  • 8Nitta K, Ishizuka T, Horita S, et al. Soluble osteopontin and vascu- lar calcification in hemodialysis patients [ J ]. Nephron, 2001, 89 (4) : 455-458.
  • 9Isoda K, Nishikawa K, Kamezawa Y, et al. Osteopontin plays an important role in the development of medial thickening and neointi- real formation [J]. Cire Res, 2002, 91(1): 77-82.
  • 10Speer MY, McKee MD, Guldberg RE, et al. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla pro- tein-deficient mice: evidence for osteopontin as an inducible inhib- itor of vascular calcification in vivo [ J]. J Exp Ned, 2002, 196 (8) : 1 047-055.

二级参考文献13

  • 1Silverman MG,Blaha MJ,Blumenthal RS. Adjunctive lipid lowering therapy in the era of surrogate endpoints[J].Cardiology in Review,2011,(01):17-22.
  • 2Farmer JA. Nicotinic acid:a new look at an old drug[J].Current Atherosclerosis Report,2009,(02):87-92.
  • 3Witkiewicz W,Czyzewska-Buczynska A,Balasz S. The role of osteopontin in cardiovascular diseases[J].Pol Merkuriusz Lek,2010,(170):79-83.
  • 4Soslow RA,Dannenberg AJ,Rush D. COX-2 is expressed in human pulmonary,colonic,and mammary tumors[J].Cancer,2000,(12):2637-2645.doi:10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B.
  • 5Lund SA,Giachelli CM,Scatena M. The role of osteopontin in inflammatory processes[J].J Cell Commun Signal,2009,(3-4):311-322.
  • 6Maziere C,Gomila C,Maziere JC. Oxidized low-density lipoprotein increases osteopontin expression by generation of oxidative stress[J].Free Radical Biology and Medicine,2010,(10):1382-1387.
  • 7陈瑶;汪翼;李倩.烟酸改善实验性肥胖大鼠血脂及血管内皮功能障碍的研究[A]济南:中华医学分会儿科学分会,200864-67.
  • 8Wu ZH,Zhao SP. Niacin promotes cholesterol efflux through stimulation of the PPAR gamma-LXR alpha-ABCA1 pathway in 3T3-L1 adipocytes[J].Pharmacology,2009,(05):282-287.doi:10.1159/000242999.
  • 9Nakamachi T,Nomiyama T,Gizard F. PPAR alpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes[J].Diabetes,2007,(06):1662-1670.
  • 10Ogawa D,Stone JF,Takata Y. Liver X receptor agonists inhibit cytokine-induced osteopontin expression in macrophages through interference with activator protein-1 signaling pathways[J].Circulation Research,2005,(07):e59-e67.

共引文献9

同被引文献25

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部